<DOC>
	<DOCNO>NCT01226745</DOCNO>
	<brief_summary>The objective active-drug Extension Study evaluate continue safety efficacy ONO-4641 ( MSC2430913A ) subject relapsing-remitting multiple sclerosis ( RRMS ) complete initial 26-week Core Study ( ONO-4641POU006 [ NCT01081782 ] ) .</brief_summary>
	<brief_title>Phase 2 Extension Trial Patients With Relapsing-Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Completed 26 week doubleblind phase Study ONO4641POU006 Presence dermatological abnormality Study ONO4641POU006 could increase risk patient develop skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>ONO-4641</keyword>
	<keyword>MSC2430913A</keyword>
	<keyword>Efficacy</keyword>
</DOC>